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Trouble with trials
While developing the Annual Evidence Update on Acne Vulgaris 
from 25 randomized controlled trials (RCTs) from 2009, Ingram 
and colleagues discovered a high frequency of problems with 
the reporting and interpretation of the data. By highlighting the 
common problems in these studies, the authors hope not only 
to reduce bias for future results but also to improve patient wel-
fare and influence the future of clinical acne trials. Interestingly, 
major problems of trial reporting were identified in 12 of these 
25 RCTs; among the issues were a lack of statistical power, dupli-
cate publication, testing of the wrong outcome, “salami publi-
cation,” absent inferiority margins, reports of two independent 
studies as one, lack of true double-blinded trials, absent data, 
data fishing, impressive P-values, and inflated odds ratios. In the 
future, such problems can be circumvented through prospective 
trial registration and adherence to the CONSORT (Consolidated 
Standards of Reporting Trials) guidelines, which provide the gold 
standard for RCT reporting. (Trials 11:77, 2010)
The underlying relationship
The incidence of malignant melanoma has been rising in pros-
perous white populations. Earlier diagnosis and a consequent 
improvement in prognosis have been achieved. In addition, 
in the United States, a systematic proportional relationship 
between incidence rates for in situ melanoma and invasive 
melanoma across all ages has been observed. Lee examined 
the Statistics Epidemiology and End Results Program of the US 
National Cancer Institute data for in situ and invasive melano-
ma in white individuals from 1975 to 2004. The log incidence 
and log invasive rate for malignant melanoma were found to 
be critical characteristics of this disease. This relationship is 
independent of year, gender, or age and is sufficiently strong 
to exclude other factors such as diagnosis or historical change. 
Furthermore, these results probably stem from individual dif-
ferences in melanoma rates and responses within popula-
tions. (Dermatol Res Pract, published online 28 June 2010; 
doi:10.1155/2010/839829)
Disappearing microneedles
The traditional intramuscular injection of influenza vaccine has 
been very successful; however, the necessary hypodermic need-
les cause needle phobia and biohazardous waste. Recently, 
Sullivan and colleagues reported the development of dissolving 
polyvinylpyrrolidone microneedle patches for influenza vac-
cination. The polymer microneedles dissolve in the skin within 
minutes and are eliminated by the body. These microneedles 
increase a vaccine’s immunogenicity by targeting the anti-
gen directly to the skin at a depth that maximizes interaction 
with the plethora of resident antigen-presenting cells. A robust 
humoral and cellular immune response was induced following 
use of this vaccination technique, which employs lyophilized 
antigen at a very low dose. In addition, a single vaccination con-
ferred protective immunity against lethal viral challenge in mice. 
Although the immunological responses were similar between 
delivery via the microneedle patch and intramuscular injection, 
an enhanced recall immune response, increased numbers of 
antibody-secreting cells, and more efficient viral clearance were 
observed after administration with the microneedle patch. Thus, 
the dissolving microneedle patches appear to provide a safer, 
more immunogenic, and logistically better approach for the 
administration of influenza vaccine, allowing for the possibility 
of increased population coverage. (Nat Med 16:915–20, 2010)
At the root of hair loss
Alopecia areata (AA) is a common autoimmune disease that 
affects 5.3 million Americans and results in loss of hair trig-
gered by the collapse of immune privilege. Because the 
underlying genetic basis of AA is unknown, Petukhova and 
colleagues performed a genome-wide association study with 
1,054 AA cases and 3,278 controls using a combination of 
Illumina 610K and 550K arrays. This analysis identified 139 
single-nucleotide polymorphisms (SNPs) that are significant-
ly associated with AA, and these SNPs clustered into eight 
genomic regions that contained genes such as CTLA4, IL-2/
IL-21, HLA, ULBP genes, and IL-2RA. Interestingly, this study 
implicated a new class of NKG2D ligands, the ULBP genes, 
in autoimmune disease. Indeed, functional studies demon-
strated that the autoimmune destruction in AA may result, in 
part, from CD8+NKG2D+ cytotoxic T cells that are activated 
by the upregulation of ULBP3 in the hair follicle. This exciting 
result offers new insight into the underlying mechanism of AA 
and provides a novel target for the development of therapies. 
(Nature 466:113–7, 2010)
Commonalities in Turkey and Japan
In two complementary studies, Remmers and Mizuki, along 
with their respective colleagues, performed genome-wide 
association studies to identify the genetic variants that under-
lie Behçet’s disease, a genetically complex disease of unknown 
origin that is prevalent in Middle Eastern countries as well as 
in Japan. Remmers and colleagues examined 311,459 single-
nucleotide polymorphisms (SNPs) from 1,215 Behçet’s cases 
and 1,278 healthy controls from Turkey, and Mizuki and col-
leagues examined 320,438 SNPs from 611 Behçet’s cases and 
737 controls from Japan. Both studies confirmed the known 
association between HLA-B*51 and this disease. After a data 
exchange between the groups to facilitate data-set validation, 
IL10 and IL23R-IL2RB2, which are critical for the immune 
response, were identified as new susceptibility loci for Behçet’s 
disease in both populations. (Nat Genet 420:698–702, 2010; 
Nat Genet 420:703–6, 2010)
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